ESMO 2017 | Searching for new agents against lung cancer: the PROFILE 1014 and ALEX trials
Luis Paz-Ares, MD, from The University Hospital 12 de Octubre, Madrid, Spain speaks to us to discuss the results of the PROFILE 1014 study (NCT01154140). This was a Phase III clinical trial comparing the efficacy of crizotinib compared to standard chemotherapy in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive lung cancer. Prof. Paz-Ares tells us how close analysis of the data may yield more information on the study’s final statistics, and gives his impressions of crizotinib’s effect on patient survival. He also discusses the ALEX study (NCT02075840), a Phase III trial comparing crizotinib with alectinib in the treatment of ALK-positive non-small cell lung cancer, explaining the results and posing a question, which further studies could address. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up